1. Blue sky break out on CASI chart
2. 52 week high on rising volume
3. Liver trial with 2076 news expected soon, but update would not come until all patients failed. This means people are living longer on 2076 then expected. Fantastic news for patients and their families.
4. Evomela approval in 3 weeks in China
5. 30 new drugs approved in USA to be manufactured and distributed in the world's largest market place by a team familiar with Chinese laws and physicians. (ANDA contains data which is submitted to FDA for the review and potential approval of a generic drug product. Once approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, lower cost alternative to the brand-name drug it references.)
6. An affordable approved drug (Entecavir) for Hepatitis B which is at epidemic levels in China now in CASI's line up.
7. 90 million in the bank for these projects plus low float
8. International experienced investors 1. ETP Global Fund LP, 2.IDG-Accel China Growth Fund III, 3.Robert W. Duggan, former Chairman and CEO of Pharmacyclics Inc backing this Chinese American pharmaceutical company
9. Now, getting noticed by Wall Street, Motley Fool and making a global presentation at H.C. Wainwright Global Life Sciences Conference, April 8 – 10, 2018
10. Management with solid connections with China: Dr. Ken Keyong Ren M.D., Ph.D., Dr. Wei-Wu He Ph.D.,Mr. James Huang Dr. Zhou and Dr. Alexander Wu. Google the credentials of these gentlemen and you will be impressed by their accomplishments in China and the USA
The world's largest marketplace China, needs affordable approved drugs and CASI will deliver on that promise.
